Is There a Place for Biologics in Acne?

Area of Science:

• Dermatology
• Immunology
• Inflammatory skin diseases

Background:

• Acne vulgaris is a complex inflammatory skin condition.
• Its pathogenesis involves follicular hyperkeratinization, sebaceous gland issues, microbial imbalance, and immune responses, notably T helper cell 1 (Th1) and T helper cell 17 (Th17) pathways.
• This understanding has prompted research into biologic therapies targeting key cytokines like TNFα, IL-1, IL-17, and IL-23.

Purpose of the Study:

• To review the immunopathogenesis of acne vulgaris.
• To critically assess the rationale, evidence, and limitations of using biologic therapies for acne treatment.
• To explore the potential role of biologics in acne-like conditions.

Main Methods:

• Literature review and synthesis of current research on acne immunopathogenesis.
• Critical evaluation of clinical trial data for biologic therapies in acne.
• Analysis of case reports and studies on biologics in severe, treatment-resistant acne and related inflammatory conditions.

Main Results:

• Clinical trials have not yet confirmed the efficacy of biologics for moderate to severe acne vulgaris.
• Some evidence suggests potential benefits of TNFα and IL-17A inhibitors in severe, treatment-resistant cases, often overlapping with hidradenitis suppurativa (HS).
• Biologics have shown effectiveness in monogenic autoinflammatory syndromes with acne-like lesions, suggesting these may represent HS or HS-like pathology.

Conclusions:

• The role of biologic therapy in acne vulgaris management remains unproven.
• Biologics may be effective for specific acne phenotypes that share characteristics with autoinflammatory diseases or hidradenitis suppurativa.
• Further research is needed to clarify the precise indications for biologic therapies in inflammatory dermatoses.